Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$40.83
-0.4%
$44.79
$35.62
$67.66
$2.00B0.84327,504 shs236,143 shs
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$64.95
-0.7%
$65.53
$36.99
$70.81
$1.38B0.79141,683 shs82,928 shs
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
$9.60
$4.35
$11.97
$1.01B4.52528,025 shs1.43 million shs
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
$28.04
$28.04
$5.62
$28.54
$807.55M2.74499,313 shs35,036 shs
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
-0.41%+5.64%-5.51%-24.22%+7.00%
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
-0.73%+0.57%-6.61%+18.87%+72.69%
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
0.00%0.00%0.00%0.00%0.00%
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
4.8369 of 5 stars
3.31.00.03.72.84.23.8
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
4.4687 of 5 stars
2.53.00.03.31.93.33.1
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/AN/AN/AN/AN/AN/AN/AN/A
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
2.50
Moderate Buy$66.0061.65% Upside
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
3.00
Buy$80.0023.17% Upside
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/AN/AN/AN/A
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
N/AN/AN/AN/A

Current Analyst Ratings

Latest DOVA, ANIP, CNTTF, and AMPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/23/2024
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$77.00
4/10/2024
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
3/15/2024
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Capital One Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$80.00
3/5/2024
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$60.00
3/5/2024
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$70.00 ➝ $77.00
3/4/2024
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$73.00 ➝ $83.00
3/1/2024
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$72.00 ➝ $80.00
2/16/2024
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$70.00 ➝ $72.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$644.40M3.10$4.35 per share9.39$13.35 per share3.06
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$486.82M2.81$6.37 per share10.20$21.13 per share3.07
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
$15.96M0.00N/AN/AN/ANaN
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
$10.35M78.02N/AN/A$2.71 per share10.35

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$137.54M$2.5815.839.930.9721.34%26.95%12.27%5/14/2024 (Estimated)
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$18.78M$0.8477.3215.69N/A3.86%18.06%8.38%5/10/2024 (Confirmed)
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/A$0.07137.180.00N/AN/AN/AN/AN/A
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
-$72.28M-$2.60N/AN/AN/A-544.09%-101.60%-67.21%N/A

Latest DOVA, ANIP, CNTTF, and AMPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/10/2024N/A
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$0.9650N/A-$0.9650N/AN/AN/A  
2/29/2024Q4 2023
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$0.58$0.78+$0.20$1.52$123.02 million$131.65 million
2/28/2024Q4 2023
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$0.84$0.81-$0.03$0.94$174.90 million$178.11 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
N/AN/AN/AN/AN/A
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
N/AN/AN/AN/AN/A
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/AN/AN/AN/AN/A
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
0.92
2.17
1.70
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
0.66
3.57
2.81
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/AN/AN/A
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
0.41
5.64
5.37

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
65.09%
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
76.05%
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
0.08%
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
33.03%

Insider Ownership

CompanyInsider Ownership
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
27.10%
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
12.70%
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/A
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
60.30%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
1,76148.87 million35.62 millionOptionable
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
64221.08 million18.40 millionOptionable
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/A105.61 millionN/ANot Optionable
Dova Pharmaceuticals Inc stock logo
DOVA
Dova Pharmaceuticals
11528.80 millionN/AOptionable

DOVA, ANIP, CNTTF, and AMPH Headlines

SourceHeadline
Cumberland Valley School Board reinstates assembly featuring ’30 Rock’ star after special meetingCumberland Valley School Board reinstates assembly featuring ’30 Rock’ star after special meeting
msn.com - April 25 at 12:26 AM
Analysis of Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology Signed During 2016-2024Analysis of Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology Signed During 2016-2024
uk.finance.yahoo.com - March 7 at 12:52 PM
Vikings at Raiders Game PreviewVikings at Raiders Game Preview
bignewsnetwork.com - December 7 at 9:23 AM
Kwality Pharmaceuticals Ltd. Share PriceKwality Pharmaceuticals Ltd. Share Price
financialexpress.com - October 17 at 10:22 AM
Dova Pin CodeDova Pin Code
indiatvnews.com - August 26 at 4:43 PM
Fulcrum swings back up after FDA lifts clinical holdFulcrum swings back up after FDA lifts clinical hold
bizjournals.com - August 22 at 5:13 PM
Plano’s Reata Pharmaceuticals Acquired by Biogen for $7.3 BillionPlano’s Reata Pharmaceuticals Acquired by Biogen for $7.3 Billion
dmagazine.com - August 4 at 3:36 PM
Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive OfficerFulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer
technews.tmcnet.com - May 15 at 8:47 AM
Sobi Emerges as Savior for CTI Biopharma Cash Crunch With $1.7B M&A DealSobi Emerges as Savior for CTI Biopharma Cash Crunch With $1.7B M&A Deal
medcitynews.com - May 12 at 2:32 AM
Sobi buys CTI BioPharma in $1.7B rare disease playSobi buys CTI BioPharma in $1.7B rare disease play
mmm-online.com - May 10 at 6:57 PM
Immune Thrombocytopenia Market 2023 Size to reach USD 3.33 Billion by 2026 With A 0.54% CAGRImmune Thrombocytopenia Market 2023 Size to reach USD 3.33 Billion by 2026 With A 0.54% CAGR
marketwatch.com - March 29 at 10:42 AM
With A 0.54% CAGR, Immune Thrombocytopenia Market 2023 Size Will Reach USD 3.33 Billion by 2026With A 0.54% CAGR, Immune Thrombocytopenia Market 2023 Size Will Reach USD 3.33 Billion by 2026
marketwatch.com - March 21 at 3:28 PM
Latest Research on Chemotherapy Induced Thrombocytopenia Drugs Market Report 2023-2029Latest Research on Chemotherapy Induced Thrombocytopenia Drugs Market Report 2023-2029
marketwatch.com - February 27 at 5:29 PM
Global Immune Thrombocytopenia Treatment Market Size To Grow On The Basis Of Refined Innovation From 2023-2030 By VMReportsGlobal Immune Thrombocytopenia Treatment Market Size To Grow On The Basis Of Refined Innovation From 2023-2030 By VMReports
marketwatch.com - February 19 at 7:23 AM
Pasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to its Board of DirectorsPasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to its Board of Directors
finance.yahoo.com - September 20 at 5:34 PM
Tethys Oil AB (TETY)Tethys Oil AB (TETY)
investing.com - September 14 at 8:09 PM
Molina Healthcare (NYSE: MOH)Molina Healthcare (NYSE: MOH)
fool.com - August 11 at 11:25 PM
UK watchdog fines Pfizer, Flynn Pharma $84 million for overcharging NHSUK watchdog fines Pfizer, Flynn Pharma $84 million for overcharging NHS
uk.news.yahoo.com - July 23 at 7:50 AM
Global Immune Thrombocytopenia Market to Rise at 0.54% CAGR from 2019-2026Global Immune Thrombocytopenia Market to Rise at 0.54% CAGR from 2019-2026
marketwatch.com - July 19 at 7:32 PM
Bone Marrow Biopsy Value Limited in Follicular Lymphoma Response AssessmentBone Marrow Biopsy Value Limited in Follicular Lymphoma Response Assessment
medpagetoday.com - July 12 at 2:09 AM
DOVA_old Historical DataDOVA_old Historical Data
investing.com - June 9 at 6:26 AM
GSKs Vi­iV de­buts next evo­lu­tion in HIV med Dova­to cam­paign with new spokes­peo­ple and new mes­sageGSK's Vi­iV de­buts next evo­lu­tion in HIV med Dova­to cam­paign with new spokes­peo­ple and new mes­sage
endpts.com - May 27 at 1:30 PM
This is not pressure - Passionate Parker issues rallying cry ahead of huge Blackburn clash'This is not pressure' - Passionate Parker issues rallying cry ahead of huge Blackburn clash
uk.finance.yahoo.com - April 30 at 8:15 PM
Ukraine Holocaust survivors find shelter in IsraelUkraine Holocaust survivors find shelter in Israel
reuters.com - April 30 at 8:15 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Amphastar Pharmaceuticals logo

Amphastar Pharmaceuticals

NASDAQ:AMPH
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
ANI Pharmaceuticals logo

ANI Pharmaceuticals

NASDAQ:ANIP
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
CannTrust logo

CannTrust

OTCMKTS:CNTTF
CannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.
Dova Pharmaceuticals logo

Dova Pharmaceuticals

NASDAQ:DOVA
Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.